

# TABLE OF CONTENTS

Preface.....	iii
Disclosure of Potential Conflicts of Interest.....	v
Continuing Pharmacy Education and Program Instructions.....	v
Endocrine I.....	1
Faculty Panel.....	3

## NEW PHARMACOTHERAPIES FOR TYPE 2 DIABETES

*By Brian Irons, Pharm.D., FCCP, BCACP, BCPS, BC-ADM*

Learning Objectives .....	5
Introduction .....	5
Clinical Guideline Updates in Drug Therapy Management .....	5
Baseline Knowledge Statements .....	5
Additional Readings .....	5
Abbreviations in This Chapter .....	6
Incretin-Based Therapies .....	9
Other Agents Now Approved for T2DM Hyperglycemia .....	14
Conversion from Oral DM Agents to Insulin-Only Therapy .....	15
Updates in Noncardiac Diabetes Drug Safety .....	16
Newer Pharmacotherapies in the Pipeline .....	18
Patient Education .....	18
References .....	19
Self-Assessment Questions .....	22

## CARDIOVASCULAR COMPLICATIONS

### IN PATIENTS WITH DIABETES

*By Karen J. McConnell, Pharm.D., BCPS (AQ Cardiology);  
and Paul B. Shaw, Pharm.D., BCPS*

Learning Objectives .....	27
Introduction .....	27
Baseline Knowledge Statements .....	27
Additional Readings .....	27
Abbreviations in This Chapter .....	28
Primary and Secondary Prevention .....	28
Diabetes Drugs and CV Risk .....	37
Patient Education .....	39
Quality Improvement .....	39
Conclusion .....	39
References .....	40
Self-Assessment Questions .....	45

## OSTEOPOROSIS

*By Alicia B. Forinash, Pharm.D., BCPS, BCACP;  
and Abigail M. Yancey, Pharm.D., BCPS*

Learning Objectives .....	51
Epidemiology .....	51
Baseline Knowledge Statements .....	51
Additional Readings .....	51
Abbreviations in This Chapter .....	52
Physiology and New Drug Target Pathways .....	52

Diagnosis .....	53
Pharmacotherapy: New Drugs and Formulations .....	53
Prevention and Treatment .....	56
Facts vs. Clinical Myths .....	61
Role of the Pharmacist .....	67
References .....	67
Self-Assessment Questions .....	73

Cardiology I.....	79
Faculty Panel.....	81

## ACUTE DECOMPENSATED HEART FAILURE

*By Kristen Bova Campbell, Pharm.D., BCPS (AQ Cardiology);  
and Michael Moranville, Pharm.D., BCPS (AQ Cardiology)*

Learning Objectives .....	83
Introduction .....	83
Baseline Knowledge Statements .....	83
Additional Readings .....	83
Abbreviations in This Chapter .....	84
Diagnosis and Prognosis .....	84
Treatment .....	85
Transitions of Care .....	96
References .....	96
Self-Assessment Questions .....	99

## NEWER ANTITHROMBOTIC AGENTS

### AND THEIR ROLE IN ACS

*By Michael P. Dorsch, Pharm.D., MS, BCPS (AQ Cardiology);  
and Kristen T. Pogue, Pharm.D., BCPS (AQ Cardiology)*

Learning Objectives .....	105
Introduction .....	105
Baseline Knowledge Statements .....	105
Additional Readings .....	105
Abbreviations in This Chapter .....	106
Clopidogrel Variability and Response .....	107
Prasugrel .....	113
Ticagrelor .....	116
Rivaroxaban .....	117
Other Antiplatelet Agents .....	118
Conclusion .....	119
References .....	120
Self-Assessment Questions .....	124

## NEWER ANTICOAGULATION STRATEGIES

### IN ATRIAL FIBRILLATION

*By Steven P. Dunn, Pharm.D., BCPS (AQ Cardiology)*

Learning Objectives .....	129
Introduction .....	129
Baseline Knowledge Statement.....	129
Additional Readings.....	129

Abbreviations in This Chapter .....	130
New Strategies for Risk Stratification in Patients with AF .....	130
New Pharmacotherapy for Stroke Prevention in AF .....	132
Conclusion .....	140
References .....	142
Self-Assessment Questions .....	145

Cardiology II.....	149
Faculty Panel.....	151

**HEART FAILURE WITH PRESERVED  
EJECTION FRACTION**

*By Sheryl L. Chow, Pharm.D., FCCP, BCPS (AQ Cardiology)*

Learning Objectives .....	153
Introduction .....	153
Baseline Knowledge Statements.....	153
Additional Readings.....	153
Abbreviations in This Chapter .....	154
Risk Factors and Lifestyle Modifications .....	156
Clinical Presentation and Diagnosis .....	157
Treatment .....	158
Conclusion .....	165
References .....	165

**CLINICAL PHARMACOGENOMICS: POTENTIAL  
IMPACT ON CARDIOVASCULAR DISEASE OUTCOMES**

*By Samuel G. Johnson, Pharm.D., BCPS (AQ Cardiology)*

Learning Objectives .....	173
Introduction .....	173
Baseline Knowledge Statements .....	173
Additional Readings .....	173
Abbreviations in This Chapter .....	174
Basic Pharmacogenomic Principles .....	174
Genomic Variation and Clopidogrel Response .....	174
CYP2C19 Genotype Nomenclature and Allele Frequencies by Race .....	175
Genomic Variation and Risk of Simvastatin-Associated Myopathy .....	180
SLCO1B1 Polymorphisms .....	181
Adrenergic Signaling Pathways .....	183
Incorporating Pharmacogenomics into Cardiovascular Pharmacotherapy .....	185
Anticipating Ethical Issues and Navigating Through the Evolving Regulatory Landscape .....	186
Conclusion .....	191
References .....	191
Self-Assessment Questions .....	201

**MEDICATION SAFETY: IMPLICATIONS FOR  
CARDIOVASCULAR HEALTH**

*By Katy E. Trinkley, Pharm.D., BCACP; and  
Robert Lee Page II, Pharm.D., MSPH, BCPS (AQ Cardiology), CGP*

Learning Objectives .....	205
Cardiovascular Pharmacovigilance .....	205
Baseline Knowledge Statements .....	205
Additional Readings .....	205
Abbreviations in This Chapter .....	206
Medication Errors in Cardiovascular Patients .....	207
Drugs with Cardiovascular Health Concerns .....	209
Conclusion .....	226
References.....	226
Self-Assessment Questions .....	232